Trump Buys SpaceX Shares After Record IPO 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SK Hynix Shares Fall as Workers Reject Wage Deal 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Tesla Raises Cybertruck Prices by $5,000 in US 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Add as a preferred source on Google
BURNABY, British Columbia, May 01, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, 2018. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4982979. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as epilepsy, migraine and pain. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Vice President, Corporate Affairs & Investor Relations
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]
